Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

746 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Després JP, et al. N Engl J Med. 2005 Nov 17;353(20):2121-34. doi: 10.1056/NEJMoa044537. N Engl J Med. 2005. PMID: 16291982 Clinical Trial.
Plasma leptin response to an epinephrine infusion in lean and obese women.
Couillard C, Mauriège P, Prud'homme D, Nadeau A, Tremblay A, Bouchard C, Després JP. Couillard C, et al. Obes Res. 2002 Jan;10(1):6-13. doi: 10.1038/oby.2002.2. Obes Res. 2002. PMID: 11786596
Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study.
Pirro M, Mauriège P, Tchernof A, Cantin B, Dagenais GR, Després JP, Lamarche B. Pirro M, et al. Atherosclerosis. 2002 Feb;160(2):377-84. doi: 10.1016/s0021-9150(01)00588-3. Atherosclerosis. 2002. PMID: 11849661
HDL particle size: a marker of the gender difference in the metabolic risk profile.
Pascot A, Lemieux I, Bergeron J, Tremblay A, Nadeau A, Prud'homme D, Couillard C, Lamarche B, Després JP. Pascot A, et al. Atherosclerosis. 2002 Feb;160(2):399-406. doi: 10.1016/s0021-9150(01)00579-2. Atherosclerosis. 2002. PMID: 11849664
Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study).
Cantin B, Després JP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, Bergeron J, Dagenais GR. Cantin B, et al. Am J Cardiol. 2002 Mar 15;89(6):662-6. doi: 10.1016/s0002-9149(01)02336-0. Am J Cardiol. 2002. PMID: 11897206
A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
Lemieux I, Laperrière L, Dzavik V, Tremblay G, Bourgeois J, Després JP. Lemieux I, et al. Atherosclerosis. 2002 Jun;162(2):363-71. doi: 10.1016/s0021-9150(01)00711-0. Atherosclerosis. 2002. PMID: 11996956 Clinical Trial.
Does correction of the friedewald formula using lipoprotein(a) change our estimation of ischemic heart disease risk? The Quebec Cardiovascular Study.
Cantin B, Lamarche B, Després JP, Dagenais GR. Cantin B, et al. Atherosclerosis. 2002 Aug;163(2):261-7. doi: 10.1016/s0021-9150(02)00034-5. Atherosclerosis. 2002. PMID: 12052472 Clinical Trial.
Prevalence of 'hypertriglyceridemic waist' in men who participated in the Quebec Health Survey: association with atherogenic and diabetogenic metabolic risk factors.
Lemieux I, Alméras N, Mauriège P, Blanchet C, Dewailly E, Bergeron J, Després JP. Lemieux I, et al. Can J Cardiol. 2002 Jul;18(7):725-32. Can J Cardiol. 2002. PMID: 12167959
Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil.
Bossé Y, Pascot A, Dumont M, Brochu M, Prud'homme D, Bergeron J, Després JP, Vohl MC. Bossé Y, et al. Genet Med. 2002 Jul-Aug;4(4):311-5. doi: 10.1097/00125817-200207000-00010. Genet Med. 2002. PMID: 12172398 Clinical Trial.
746 results
Jump to page
Feedback